Waander L Van Heerde

List of Publications by Year
in descending order

69	3,144	218677	155660
papers	citations	26 h-index	55 g-index

69	69	69	4165
all docs	docs citations	times ranked	citing authors

#	Article	IF	Citations
1	Visualisation of cell death in vivo in patients with acute myocardial infarction. Lancet, The, 2000, 356, 209-212.	13.7	414
2	Proteome-wide Analysis and CXCL4 as a Biomarker in Systemic Sclerosis. New England Journal of Medicine, 2014, 370, 433-443.	27.0	365
3	F8 gene mutation type and inhibitor development in patients with severe hemophilia A: systematic review and meta-analysis. Blood, 2012, 119, 2922-2934.	1.4	305
4	Factor VIII gene (F8) mutation and risk of inhibitor development in nonsevere hemophilia A. Blood, 2013, 122, 1954-1962.	1.4	188
5	Cardiomyocyte Death Induced by Myocardial Ischemia and Reperfusion. Circulation, 2000, 102, 1564-1568.	1.6	157
6	A Dominant-NegativeGFI1BMutation in the Gray Platelet Syndrome. New England Journal of Medicine, 2014, 370, 245-253.	27.0	152
7	C677T methylenetetrahydrofolate reductase polymorphism interferes with the effects of folic acid and zinc sulfate on sperm concentration. Fertility and Sterility, 2003, 80, 1190-1194.	1.0	110
8	SELDI-TOF-MS of saliva: Methodology and pre-treatment effects. Journal of Chromatography B: Analytical Technologies in the Biomedical and Life Sciences, 2007, 847, 45-53.	2.3	107
9	Detection of antibody-mediated reduction of annexin A5 anticoagulant activity in plasmas of patients with the antiphospholipid syndrome. Blood, 2004, 104, 2783-2790.	1.4	94
10	Multicolor flow cytometry for evaluation of platelet surface antigens and activation markers. Thrombosis Research, 2012, 130, 92-98.	1.7	82
11	Proteomic analysis of plasma identifies the Toll-like receptor agonists S100A8/A9 as a novel possible marker for systemic sclerosis phenotype. Annals of the Rheumatic Diseases, 2014, 73, 1585-1589.	0.9	79
12	Improvements in Factor VIII Inhibitor Detection: From Bethesda to Nijmegen. Seminars in Thrombosis and Hemostasis, 2009, 35, 752-759.	2.7	67
13	C-Reactive Protein and Annexin A5 Bind to Distinct Sites of Negatively Charged Phospholipids Present in Oxidized Low-Density Lipoprotein. Arteriosclerosis, Thrombosis, and Vascular Biology, 2005, 25, 717-722.	2.4	65
14	Reduction of circulating annexin A5 levels and resistance to annexin A5 anticoagulant activity in women with recurrent spontaneous pregnancy losses. American Journal of Obstetrics and Gynecology, 2006, 194, 182-188.	1.3	58
15	Global haemostasis assays, from bench to bedside. Thrombosis Research, 2012, 129, 681-687.	1.7	52
16	Risk factors and prognosis of young stroke. The FUTURE study: A prospective cohort study. Study rationale and protocol. BMC Neurology, 2011, 11, 109.	1.8	51
17	A novel hemostasis assay for the simultaneous measurement of coagulation and fibrinolysis. Hematology, 2011, 16, 327-336.	1.5	51
18	Gout Is a Chronic Inflammatory Disease in Which High Levels of Interleukinâ€8 (CXCL8), Myeloidâ€Related Protein 8/Myeloidâ€Related Protein 14 Complex, and an Altered Proteome Are Associated With Diabetes Mellitus and Cardiovascular Disease. Arthritis and Rheumatology, 2015, 67, 3303-3313.	5.6	51

#	Article	IF	Citations
19	Salivary Protein/Peptide Profiling with SELDI-TOF-MS. Annals of the New York Academy of Sciences, 2007, 1098, 498-503.	3.8	47
20	Hemorrhagic disorders of fibrinolysis: a clinical review. Journal of Thrombosis and Haemostasis, 2018, 16, 1498-1509.	3.8	47
21	Thrombocytopenia in early malaria is associated with GP1b shedding in absence of systemic platelet activation and consumptive coagulopathy. British Journal of Haematology, 2010, 151, 495-503.	2.5	43
22	Prophylactic effect of recombinant factor VIIa in factor VII deficient patients. British Journal of Haematology, 2004, 125, 494-499.	2.5	37
23	Defective apoptosis of peripheral-blood lymphocytes in hyper-IgD and periodic fever syndrome. Blood, 2007, 109, 2416-2418.	1.4	36
24	Improved neurocognitive functions correlate with reduced inflammatory burden in atrial fibrillation patients treated with intensive cholesterol lowering therapy. Journal of Neuroinflammation, 2013, 10, 78.	7.2	33
25	Platelet CD34 expression and Î±/Í´-granule abnormalities in GFI1B- and RUNX1-related familial bleeding disorders. Blood, 2017, 129, 1733-1736.	1.4	28
26	Platelet-Rich Plasma Can Replace Fetal Bovine Serum in Human Meniscus Cell Cultures. Tissue Engineering - Part C: Methods, 2013, 19, 892-899.	2.1	27
27	Differential tissue expression of Annexin VIII in human. FEBS Letters, 1994, 349, 120-124.	2.8	26
28	Retrospective evaluation of bleeding tendency and simultaneous thrombin and plasmin generation in patients with rare bleeding disorders. Haemophilia, 2012, 18, 630-638.	2.1	26
29	Increased volume of distribution for recombinant activated factor VII and longer plasma-derived factor VII half-life may explain their long lasting prophylactic effect. Thrombosis Research, 2013, 132, 256-262.	1.7	24
30	Hemostatic alterations during coronary artery bypass grafting. Thrombosis Research, 2016, 140, 140-146.	1.7	21
31	Persisting thrombin activity in elderly patients with atrial fibrillation on oral anticoagulation is decreased by anti-inflammatory therapy with intensive cholesterol-lowering treatment. Journal of Clinical Lipidology, 2011, 5, 273-280.	1.5	20
32	Bleeding severity in patients with rare bleeding disorders: real-life data from the RBiN study. Blood Advances, 2020, 4, 5025-5034.	5.2	19
33	Plasma annexin A5 level relates inversely to the severity of coronary stenosis. Biochemical and Biophysical Research Communications, 2007, 356, 674-680.	2.1	17
34	Salivary biomarkers associated with perceived satiety and body mass in humans. Proteomics - Clinical Applications, 2007, 1, 1637-1650.	1.6	16
35	Pharmacodynamic monitoring of factor VIII replacement therapy in hemophilia A: Combining thrombin and plasmin generation. Journal of Thrombosis and Haemostasis, 2020, 18, 3222-3231.	3.8	16
36	Diagnostic work up of patients with increased bleeding tendency. Haemophilia, 2020, 26, 269-277.	2.1	16

#	Article	IF	Citations
37	Thirteen novel mutations in the factor VIII gene in the Nijmegen haemophilia A patient population. British Journal of Haematology, 2005, 131, 109-117.	2.5	15
38	Clinical phenotype in genetically confirmed von Willebrand disease type 2N patients reflects a haemophilia A phenotype. Haemophilia, 2015, 21, e375-83.	2.1	14
39	Whole exome sequencing in the diagnostic workup of patients with a bleeding diathesis. Haemophilia, 2019, 25, 127-135.	2.1	14
40	Polymorphisms in the Annexin A5 gene influence circulating Annexin A5 levels in healthy controls. Thrombosis Research, 2012, 129, 815-817.	1.7	13
41	The â^'1C>T mutation in the annexin A5gene does not affect plasma levels of annexin A5. Blood, 2003, 101, 4223-4224.	1.4	12
42	Salvia Miltiorrhiza Root Water-Extract (Danshen) Has No Beneficial Effect on Cardiovascular Risk Factors. A Randomized Double-Blind Cross-Over Trial. PLoS ONE, 2015, 10, e0128695.	2.5	11
43	Thrombin and plasmin generation in patients with plasminogen or plasminogen activator inhibitor type 1 deficiency. Haemophilia, 2019, 25, 1073-1082.	2.1	11
44	Search for Breast Cancer Biomarkers in Fractionated Serum Samples by Protein Profiling With SELDIâ€TOF MS. Journal of Clinical Laboratory Analysis, 2012, 26, 1-9.	2.1	10
45	Alterations in markers of coagulation and fibrinolysis in patients with Paroxysmal Nocturnal Hemoglobinuria before and during treatment with eculizumab. Thrombosis Research, 2015, 136, 274-281.	1.7	10
46	The impact of exercise-induced core body temperature elevations on coagulation responses. Journal of Science and Medicine in Sport, 2017, 20, 202-207.	1.3	10
47	Treatment of patients with rare bleeding disorders in the Netherlands: Realâ€life data from the RBiN study. Journal of Thrombosis and Haemostasis, 2022, 20, 833-844.	3.8	9
48	Pharmacodynamics of recombinant activated factor VII and plasma-derived factor VII in a cohort of severe FVII deficient patients. Thrombosis Research, 2013, 132, 116-122.	1.7	8
49	Annexin A5 haplotypes in familial hypercholesterolemia: Lack of association with carotid intima-media thickness and cardiovascular disease risk. Atherosclerosis, 2015, 238, 195-200.	0.8	8
50	Combining factor VIII levels and thrombin/plasmin generation: A population pharmacokineticâ€pharmacodynamic model for patients with haemophilia A. British Journal of Clinical Pharmacology, 2022, 88, 2757-2768.	2.4	6
51	Idiopathic Factor VIII Inhibitor Autoantibody in a Man Presented After Accident. Clinical and Applied Thrombosis/Hemostasis, 2009, 15, 588-590.	1.7	5
52	Annexin A5 haplotypes in the antiphospholipid syndrome. Thrombosis Research, 2015, 135, 417-419.	1.7	5
53	Von Willebrand disease type 2M: Correlation between genotype and phenotype. Journal of Thrombosis and Haemostasis, 2022, 20, 316-327.	3.8	5
54	Fibrinolytic assays in bleeding of unknown cause: Improvement in diagnostic yield. Research and Practice in Thrombosis and Haemostasis, 2022, 6, e12681.	2.3	5

#	Article	IF	Citations
55	No association between <scp>A</scp>nnexin <scp>A</scp>5 genetic variants and deep venous thrombosis. British Journal of Haematology, 2015, 169, 301-304.	2.5	4
56	Pharmacokinetics and pharmacodynamics of a recombinant fusion protein linking activated coagulation factor VII with human albumin (rVIIa-FP) in patients with congenital FVII deficiency. Hematology, 2020, 25, 17-25.	1.5	4
57	Effect of emicizumab on thrombin generation: A case report of breakthrough bleeding during emicizumab treatment. Haemophilia, 2020, 26, e327-e330.	2.1	4
58	Diagnosis of rare bleeding disorders. Haemophilia, 2021, 27, 60-65.	2.1	3
59	No Association Between Normalization of VWF Levels and Bleeding Phenotype in Patients with Type 1 VWD - from the Win Study. Blood, 2016, 128, 2577-2577.	1.4	3
60	Acquired von Willebrand Disease Associated with Mantle Cell Lymphoma. Case Reports in Hematology, 2018, 2018, 1-3.	0.4	2
61	Desmopressin response depends on the presence and type of genetic variants in patients with type 1 and type 2 von Willebrand disease. Blood Advances, 2022, 6, 5317-5326.	5.2	2
62	Diagnosis of rare bleeding disorders. Haemophilia, 2022, 28, 119-124.	2.1	2
63	Do latex-based immunoturbidimetric assays conquer a prominent role in von Willebrand factor activity detection?. Thrombosis Research, 2014, 134, 531-532.	1.7	1
64	A Dominant-Negative GFI1B Mutation in Gray Platelet Syndrome. Blood, 2013, 122, LBA-3-LBA-3.	1.4	1
65	Reply of the Authors:. Fertility and Sterility, 2004, 81, 1430-1431.	1.0	0
66	Identification of 18 High Risk F8 Mutations for Inhibitor Development in 2,700 Non-Severe Hemophilia A Patients. Tijdschrift Voor Kindergeneeskunde, 2013, 81, 38-38.	0.0	0
67	The Plasma Concentration of the Antithrombotic Protein Annexin A5 Is Elevated in Sickle Cell Disease and Rises Further during Painful Crisis. Blood, 2008, 112, 4820-4820.	1.4	0
68	Activation of hemostatic pathways by exercise induced hyperthermia. FASEB Journal, 2012, 26, 1084.10.	0.5	0
69	Von Willebrand disease type 2M: Correlation between genotype and phenotype: Reply to comment from Dr. Favaloro and to comment from Dr. Woods et al. Journal of Thrombosis and Haemostasis, 2022, 20, 1023-1027.	3.8	0